Kathryn Chatterton
Papers
4
Total Citations
351
H-Index
3
About
Kathryn Chatterton is a leading urological surgeon and researcher whose work is reshaping the surgical management of bladder cancer. Her primary research focuses on comparing robot-assisted radical cystectomy (RARC) with intracorporeal urinary diversion against the traditional open approach. Her landmark 2022 study, cited over 320 times, provided pivotal evidence that robot-assisted surgery does not significantly reduce 90-day morbidity or mortality compared to open surgery—a finding that has directly influenced clinical guidelines and surgical decision-making worldwide. Chatterton has also advanced the conversation on healthcare value; her 2023 cost-effectiveness analysis demonstrated that robot-assisted cystectomy offers comparable outcomes to open surgery but at a significantly higher cost, prompting critical discussions on resource allocation. Her more recent work explores adverse pathological upstaging in muscle-invasive bladder cancer and the timing of urethrectomy, further refining surgical protocols. Through rigorous, high-impact comparative effectiveness research, Chatterton has established herself as a key voice in evidence-based urologic oncology, challenging assumptions and driving more informed, value-conscious care for bladder cancer patients.
Research Focus
Key Achievements
Top Papers
- 1
- 2
- 3
- 4